A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancerGenetic unmasking of an epigenetically silenced microRNA in human cancer cellsPalbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaCpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer.USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.A microRNA DNA methylation signature for human cancer metastasis.The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer.Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β PathwayTherapeutic editing of hepatocyte genome in vivo.Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis.IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.To clear, or not to clear (senescent cells)? That is the question.Epigenetic disruption of cadherin-11 in human cancer metastasis.Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer.Splicing regulator SLU7 is essential for maintaining liver homeostasis.Strategies for HCC target discovery.Uncovering the role of USP54 in cancer.DNA sensing in senescence.Hepatocellular carcinoma: killing one bird with two stonesFunctional screening to identify senescence regulators in cancerIron overload and liver cancerβ-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular CarcinomaPhenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC PolypharmacologyMouse models of oncoimmunology in hepatocellular carcinoma
P50
Q27853127-81436F5B-93ED-4CF7-896E-41B2F3CCE26AQ28288806-3610D6F1-220C-43FE-994C-BF44E52CD4E4Q33907588-D29DDFBB-17D1-4F97-8F94-756ECD95B426Q33954847-39E44B4F-933A-4699-9569-65692DC0D98CQ34342934-0B666BD5-6DB6-4888-AD1C-CB1A28B446F1Q34430590-CE35343C-A5F5-4D67-90DD-9563C78F8047Q36268425-69781936-CE3F-42DD-973A-E3EB16C433CFQ36861111-CB5189F4-887B-4706-9AEA-EE2DC32AB7FFQ37142007-D4784021-6DB9-4EA4-B852-D7D608BF196EQ37710526-F78389FF-C6FE-482E-9557-A7AC5219CB96Q38681474-D5F2F0A9-2039-4806-B398-9BB2CE361AC9Q38716318-1356B288-6273-4E42-B556-41B173279D09Q38747068-D117C7A7-65BE-4B52-A1C8-98CF0A590DD9Q38896940-B880505F-B32F-475C-A688-F4E8A28D23E3Q39388476-EF4D0D55-B2E7-40BC-BC32-10A5D72F8CF4Q39448917-B23A8860-7734-4288-9D04-8F1424AB990DQ41205843-FBCCE380-3DF9-4799-A7D0-3D63B6E3EA2EQ42279365-322B1610-0B3E-49CD-90DF-C27404A7F419Q42315748-6ADE9F60-2D7F-4365-802D-2FC574E56BEBQ50264136-68FEE466-90A2-412D-84B1-538FBE75ED75Q91928612-A1B7D45E-AA2A-4393-8149-2B93A07A146BQ92408302-5A3BA9AD-4B75-4429-A1B5-F8904BF74AAFQ92459412-68C0E84A-6109-44FA-8DBA-F353547F28A6Q92665666-B7208DD5-F8D0-4153-8423-FB1805C015B9Q92859614-E5AB50F6-B78C-49BB-86A5-C682BC56935AQ93194676-1315A104-100D-4206-85B1-3C8A86F61B04
P50
description
Spaans onderzoekster
@nl
researcher ORCID id 0000-0002-2798-1481
@en
name
Amaia Lujambio
@ast
Amaia Lujambio
@en
Amaia Lujambio
@es
Amaia Lujambio
@eu
Amaia Lujambio
@nl
Amaia Lujambio
@sl
type
label
Amaia Lujambio
@ast
Amaia Lujambio
@en
Amaia Lujambio
@es
Amaia Lujambio
@eu
Amaia Lujambio
@nl
Amaia Lujambio
@sl
prefLabel
Amaia Lujambio
@ast
Amaia Lujambio
@en
Amaia Lujambio
@es
Amaia Lujambio
@eu
Amaia Lujambio
@nl
Amaia Lujambio
@sl
P106
P1153
23470241600
P19
P21
P27
P31
P3218
P496
0000-0002-2798-1481
P569
1982-01-16T00:00:00Z